PSA as a Predictive Tool for Detecting Bone Metastases in Bone Scan

Abstract

Introduction: PSA is considered as a tumor marker for prostate cancer which has helped since its first application in the early detection, prognosis and follow up of patients with prostate cancer. In our study we collect the results of bone scans of patients with prostate cancer and correlate them with their serum PSA value to predict the efficacy of PSA value in predicting bone metastases. Material and methods: Our study was in 102 patients with prostate adenocarcinoma who were treated in our urology center and sent for staging in the nuclear medicine Lab for bone isotope scan for the detection of bone metastases in addition to the collection of their PSA value and the comparison between scan results and PSA value. Results: We divided our patients into two groups according to their PSA value considering the first one with patients of PSA more than 20ng/ml and the second group with PSA of less than or equal to 20ng/ml. The results were 82.7% of patients with PSA more than 20ng/ml to have a positive scan with bone metastases and 82% of patients with PSA less than or equal to 20ng/ml to have a negative scan. Conclusion: PSA can be considered as a good tool for the prediction of bone metastases in patients with prostate cancer especially for patients with a PSA value of 20 ng/ml and more, and as an accepted tool when the PSA value is 10-20 ng/ml.